Associate Professor, Medicine, UCLA School of Medicine
Gastroenterology
Dr. Sammy Saab, MD
|
|
Give Review
Sammy Saab is an expert in the field of Gastroenterology. She went to David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is one of the top medical schools in the US. David Geffen School of Medicine at UCLA is ranked 13 in research and 7 in primary care medicine She has 4 awards "Top Doctors:LA Area", "Top Doctors:Southern California", "Fellow (AGAF)" and "Super Doctor". Doctor Sammy Saab, MD has written publications. She has 48 publications published with PubMed. The lastest publication is: 'Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma.' She accepts Medicare.
Publications
- Probiotics are Helpful in Hepatic Encephalopathy: A Meta-Analysis of Randomized Trials.
- Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients.
- Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma.
- Hepatitis C Infection in the Elderly.
- Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors.
- Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
- The outcomes of adult liver transplants in the United States from 1987 to 2013.
- Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis.
- The impact of obesity on patient survival in liver transplant recipients: a meta-analysis.
- Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
- Hepatitis C Virus Infection Is Systemic: Meeting Additional Goals.
- Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for Treatment of Gastric Varices: Review and Meta-Analysis.
- The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17Â 000 HCV-infected transplant recipients.
- Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply.
- Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
- Kidney Transplantation Threshold in Patients With Hepatitis C: A Decision Analysis Model.
- The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85Â 000 liver transplant recipients in the US.
- Patients with nodular regenerative hyperplasia should be considered for hepatocellular carcinoma screening.
- Cirrhosis Regression in Patients With Viral Hepatitis B and C: A Systematic Review.
- The Portrait of an Adult Liver Transplant Recipient in the United States From 1987 to 2013.
- Hepatitis C disease severity in living versus deceased donor liver transplant recipients: An extended observation study.
- The Role of Mammalian Target of Rapamycin Inhibitors in the Management of Posttransplant Malignancy.
- Boceprevir in liver transplant recipients.
- Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation.
- Effects of Clostridium difficile Infection in Patients With Alcoholic Hepatitis.
- The impact of hepatitis C burden: an evidence-based approach.
- Impact of nutrition and obesity on chronic liver disease.
- Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review.
- Hepatitis C and Work Impairment: A Review of Current Literature.
- The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C: Results From an Analysis of Data From a Department of Veterans Affairs Clinical Reg...
- Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity.
- Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection.
- Inpatient Economic and Mortality Assessment for Liver Transplantation: A Nationwide Study of the United States Data from 2005 to 2009.
- Impact of coffee on liver diseases: a systematic review.
- Can Daily Coffee Consumption Reduce Liver Disease-Related Mortality?
- External validation of the risk-prediction model for hepatocellular carcinoma [hcc] from the reveal HCV study.
- Hyponatremia: clinical associations, prognosis, and treatment in cirrhosis.
- Trends in viral hepatitis cost-effectiveness studies.
- Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review.
- Simultaneous liver-kidney transplantation summit: current state and future directions.
- Endoscopic treatment with multiple stents for post-liver-transplantation nonanastomotic biliary strictures.
- Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis.
- Viral hepatitis in incarcerated adults: a medical and public health concern.
- Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis.
- Treating hepatitis C in the prison population is cost-saving.
- Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding: Preliminary Results.
- Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults.
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- Top Doctors:LA Area
- Top Doctors:Southern California
- Fellow (AGAF)
- Super Doctor
Education
-
UCLA Medical Center -
University of California San Diego -
David Geffen School of Medicine at UCLA
Hospital
-
Ronald Reagan UCLA Medical Center
Drug Facts
| NPI NUMBER | 1720008899 | |
| NPPES Provider LastName | SAAB | |
| NPPES Provider FirstName | SAMMY | |
| NPPES Provider ZIPCode | 90095 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 5186.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 27.0 | |
| Percent Opioid Claims | 0.52 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720008899 |
| Last Name Of The Provider | SAAB |
| First Name Of The Provider | SAMMY |
| View All |
Similar Doctors
|
Dr. Danice Hertz, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Mitchell J. Spirt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marvin Derezin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James L. Buxbaum, MD |
|
|
Dr. Marc D. Makhani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Wintroub, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Arash I. Zarimani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Arnold R. Savage, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary Gitnick, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Bikram S. Padda, MD |